Drug Interaction Report
1 potential interaction and/or warning found for the following 2 drugs:
- Azulfidine EN-tabs (sulfasalazine)
- niraparib
Interactions between your drugs
sulfaSALAzine niraparib
Applies to: Azulfidine EN-tabs (sulfasalazine), niraparib
MONITOR: Coadministration with niraparib may increase the plasma concentrations of drugs that are substrates of the breast cancer resistance protein (BCRP) transporter. The proposed mechanism is BCRP inhibition by niraparib. In vitro studies have shown that niraparib is able to inhibit BCRP, but a clinically meaningful interaction is unlikely.
MANAGEMENT: Caution is recommended if niraparib is used in combination with substrates of the breast cancer resistance protein (BCRP) transporter such as irinotecan, rosuvastatin, simvastatin, atorvastatin, and/or methotrexate. Monitoring for signs and symptoms of increased exposure to the BCRP substrate should be considered whenever niraparib is added to or withdrawn from therapy.
References (6)
- (2023) "Product Information. Akeega (abiraterone-niraparib)." Janssen Biotech, Inc.
- (2023) "Product Information. Zejula (niraparib)." GlaxoSmithKline
- (2023) "Product Information. Zejula (niraparib)." GlaxoSmithKline Inc
- (2023) "Product Information. Akeega (abiraterone-niraparib)." Janssen Inc
- (2023) "Product Information. Zejula (niraparib)." GlaxoSmithKline Australia Pty Ltd
- (2023) "Product Information. Zejula (niraparib)." GlaxoSmithKline UK Ltd
Drug and food interactions
No alcohol/food interactions were found with the drugs in your list. However, this does not necessarily mean no food interactions exist. Always consult your healthcare provider.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Report options
- Switch to consumer interaction data
- Email this report to a friend, doctor, or patient
- Ask questions, find answers
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Entyvio
Entyvio (vedolizumab) is used to treat ulcerative colitis (UC) and Crohn's disease, reducing ...
Skyrizi
Skyrizi (risankizumab) is used to treat plaque psoriasis, psoriatic arthritis, ulcerative colitis ...
Taltz
Taltz (ixekizumab) is used to treat plaque psoriasis, psoriatic arthritis, and ankylosing ...
Omvoh
Omvoh is used to treat moderate to severe ulcerative colitis or Crohn's disease in adults. This ...
Stelara
Stelara (ustekinumab) is used to treat Crohn's disease, ulcerative colitis, plaque psoriasis, and ...
Celebrex
Celebrex is a nonsteroidal anti-inflammatory drug used to treat pain or inflammation. Learn about ...
Humira
Humira is a tumor necrosis factor blocker used to treat many inflammatory conditions in adults ...
Rinvoq
Rinvoq (upadacitinib) is used to treat rheumatoid arthritis, psoriatic arthritis, atopic ...
Plaquenil
Plaquenil is used to treat or prevent malaria and to treat the symptoms of rheumatoid arthritis ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.